Evidence map›Paper›PMID 32559272›Full record

Trial reportThe American journal of clinical nutrition2020

Exploring the effect of vitamin D3 supplementation on surrogate biomarkers of cholesterol absorption and endogenous synthesis in patients with type 2 diabetes-randomized controlled trial.

Huicui Meng, Nirupa R Matthan, Edith Angellotti, Anastassios G Pittas, Alice H Lichtenstein

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of clinical nutrition, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01736865 (Vitamin D for Established Type 2 Diabetes), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01736865 phase2 / phase3completednot on this map

Vitamin D for Established Type 2 Diabetes (DDM2)

TypeinterventionalSponsorTufts Medical CenterRan2012 to 2015Enrolled127ConditionsType 2 DiabetesArmsCholecalciferol, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Huicui MengJean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.
Nirupa R MatthanJean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.
Edith AngellottiDivision of Endocrinology, Diabetes and Metabolism, Tufts Medical Center, Boston, MA, USA.
Anastassios G PittasDivision of Endocrinology, Diabetes and Metabolism, Tufts Medical Center, Boston, MA, USA.
Alice H LichtensteinJean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.
Tufts University · USTufts Medical Center · US

Funding

LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI MEINZEN-DERR, JAREEN, STRAWN, JEFFREY ROBERT · 2015 to 2024
$37.5M
TUFTS CLINICAL AND TRANSLATION SCIENCE INSTITUTE (UL1): BPCAUL1RR025752 · NCRR · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2008 to 2011
$17.6M
Vitamin D and Calcium Homeostasis in Relation to Type 2 DiabetesR01DK076092 · NIDDK · TUFTS MEDICAL CENTER · PI PITTAS, ANASTASSIOS G · 2006 to 2015
$4.1M
NCATS NIH HHS UL1 TR001425NCRR NIH HHS UL1 RR025752NIDDK NIH HHS R01 DK076092
6 · The paper itself

Abstract

backgroundInverse associations have been reported between serum 25-hydroxyvitamin D [25(OH)D] and circulating cholesterol concentrations in observational studies. Postulated mechanisms include reduced bioavailability of intestinal cholesterol and alterations in endogenous cholesterol synthesis.

objectiveTo explore the effect of daily supplementation with 4000 IU/d vitamin D3 for 24 wk on surrogate biomarkers of cholesterol absorption (campesterol and β-sitosterol) and endogenous synthesis (lathosterol and desmosterol).

methodsAncillary study of The Vitamin D for Established Type 2 Diabetes (DDM2) trial. Patients with established type 2 diabetes (N = 127, 25-75 y, BMI 23-42 kg/m2) were randomly assigned to receive either 4000 IU vitamin D3 or placebo daily for 24 wk. Of participants without changes in cholesterol-lowering medications (n = 114), plasma surrogate cholesterol absorption and endogenous synthesis biomarker concentrations were measured and merged with available measures of serum LDL cholesterol and HDL cholesterol concentrations.

resultsAt week 24, vitamin D3 supplementation significantly increased 25(OH)D concentrations (+21.5 ± 13.4 ng/mL) but not insulin secretion rates (primary outcome of the parent study) as reported previously. In this ancillary study there was no significant effect of vitamin D3 supplementation on serum cholesterol profile or surrogate biomarkers of cholesterol absorption and endogenous synthesis. Compared with participants not treated with cholesterol-lowering medications, those who were treated exhibited a greater reduction in plasma campesterol concentrations in the vitamin D3 but not placebo group (P-interaction = 0.011). Analyzing the data on the basis of cholesterol absorption status (hypo- versus hyperabsorbers) or cholesterol synthesis status (hypo- versus hypersynthesizers) did not alter these results.

conclusionsVitamin D3 supplementation for 24 wk had no significant effect on surrogate biomarkers of cholesterol absorption or endogenous synthesis, consistent with the lack of effect on serum cholesterol profile. Vitamin D3 supplementation resulted in greater reduction in campesterol concentrations in participants not using compared with those using cholesterol-lowering medications. Further studies are required.This trial was registered at clinicaltrials.gov as NCT01736865.

Indexed as

AgedBiomarkersCalcium-Regulating Hormones and AgentsCholecalciferolCholesterolDiabetes Mellitus, Type 2Dietary SupplementsFemaleHumansMaleMiddle AgedBiomarkersCalcium-Regulating Hormones and AgentsCholecalciferolCholesterolabsorptionbiological availabilitycholecalciferolcholesterol/biosynthesischolesterol/metabolismHDL cholesterolhydroxymethylglutaryl-CoA reductase inhibitorsLDL cholesteroltype 2 diabetes mellitusvitamin D

Identifiers

PMID32559272
PMCPMC7458767
OpenAlexW3036456676

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.